oesophageal cancer
Conditions
Brief summary
Disease-free survival (DFS), defined as the time elapsed between inclusion and locoregional or distant disease recurrence or death, whichever comes first.
Detailed description
Proportion of patients who develop locoregional disease recurrence, proportion of patients who develop distant metastases, Serious adverse events and grade 3-4 adverse events from the time of their first treatment with nivolumab according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0)
Interventions
DRUGOPDIVO 10 mg/mL concentrate for solution for infusion.
Sponsors
Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Disease-free survival (DFS), defined as the time elapsed between inclusion and locoregional or distant disease recurrence or death, whichever comes first. | — |
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients who develop locoregional disease recurrence, proportion of patients who develop distant metastases, Serious adverse events and grade 3-4 adverse events from the time of their first treatment with nivolumab according to the Common Terminology Criteria for Adverse Events (CTCAE version 5.0) | — |
Countries
Netherlands
Outcome results
None listed